Solid Biosciences Inc.
SLDB
$2.55
$0.031.19%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 96.43M | 76.56M | 76.56M | 76.56M | 76.56M |
| Gross Profit | -96.43M | -76.56M | -76.56M | -76.56M | -76.56M |
| SG&A Expenses | 33.30M | 30.98M | 29.54M | 28.34M | 27.75M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 129.73M | 112.10M | 100.03M | 99.15M | 104.32M |
| Operating Income | -129.73M | -112.10M | -100.03M | -99.15M | -104.32M |
| Income Before Tax | -124.70M | -102.44M | -90.69M | -90.25M | -96.02M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -124.70 | -102.44 | -90.69 | -90.25 | -96.02 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -124.70M | -102.44M | -90.69M | -90.25M | -96.02M |
| EBIT | -129.73M | -112.10M | -100.03M | -99.15M | -104.32M |
| EBITDA | -127.27M | -109.92M | -97.67M | -96.92M | -101.73M |
| EPS Basic | -3.04 | -3.04 | -3.30 | -3.94 | -4.84 |
| Normalized Basic EPS | -1.90 | -1.90 | -2.06 | -2.46 | -3.03 |
| EPS Diluted | -3.04 | -3.05 | -3.30 | -3.94 | -4.84 |
| Normalized Diluted EPS | -1.90 | -1.90 | -2.06 | -2.46 | -3.03 |
| Average Basic Shares Outstanding | 163.24M | 140.77M | 119.38M | 98.11M | 79.53M |
| Average Diluted Shares Outstanding | 163.24M | 140.77M | 119.38M | 98.11M | 79.53M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |